Picture EBD Group ChinaBio Partnering Forum 2022 650x100

Document › Details

Agilent Technologies Inc.. (11/16/18). "Press Release: Agilent Expands Cell Analysis R&D Capabilities in Ireland. New Facility Incorporates Recently Acquired Luxcel Biosciences". Santa Clara, CA.

	Region	Ireland, Republic of
	Organisation	Agilent Technologies Ireland Ltd.
	Product	cell analysis technology
	Product 2	business development (state/region)
	Index term	Luxcel Biosciences–Agilent: investment, 201801 acquisition €na of Luxcel by Agilent
	Person	Christian, Todd (Agilent 201506 Senior Director Global Segment Marketing before Guava Technologies)
	Person 2	Shanahan, Martin (Ireland (govt) 201811 CEO of IDA Ireland)

Agilent Technologies Inc. (NYSE: A) today announced the opening of a new, purpose-built extension to its Little Island, Cork facility in Ireland. The campus will focus on developing advanced technologies for the analysis of live-cells in real-time.

The expanded state-of-the-art facility incorporates recently acquired Luxcel Biosciences, adding real-time, fluorescence plate reader-based in vitro cell assay kits to Agilent's cell analysis portfolio. The complex will house two new laboratories, one dedicated to cell analysis technologies, and the other to develop biosensors and related bio assay solutions.

Agilent entered the cell analysis market in 2015 with the acquisition of Seahorse Bioscience, a leader in the development of specialized instruments and live-cell, kinetic assays. The addition of Luxcel expands Agilent's cell analysis portfolio and brings new capabilities through technology and research which will drive advancements in this fast-evolving field for Agilent globally.

"Technological progression allowing researchers to examine cell health and function kinetically, and in real-time, are driving global demand for complete cell analysis solutions," said Todd Christian, general manager, Agilent Cell Analysis Division. "The Luxcel acquisition and Agilent Ireland expansion underscore Agilent's continued commitment to the growing cell analysis market."

"We're excited that Agilent has invested in Ireland," said Martin Shanahan, chief executive officer, IDA Ireland. "Luxcel has partnerships and active research programs in Ireland, and with major EU and UK research institutions. This expansion will not only provide the most up-to-date and advanced solutions for Agilent's customers but will have a significant positive impact within the Irish and European innovation ecosystem."

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics, and applied chemical markets. With more than 50 years of insight and innovation, Agilent instruments, software, services, solutions, and people provide trusted answers to customers' most challenging questions. The company generated revenues of $4.47 billion in fiscal 2017 and employs 14,500 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to our Newsroom.

Contact

Victoria Wadsworth-Hansen
+1 408 553 2005
+ 45 29336980
victoria.wadsworth-hansen@agilent.com

Record changed: 2018-12-13